The efficacy of giritinib (segatan) in FLT3 mutant acute myeloid leukemia

Gilitinib is an oral selective FLT3tyrosine kinase inhibitor specifically targeted at patients with acute myeloid leukemia (AML) who carry FLT3 mutations. FLT3mutations account for approximately 25%-30% of AML and are often associated with poor prognosis and increased risk of relapse. Giritinib specifically inhibits the abnormal activation of FLT3 receptors and blocks downstream signaling pathways, thereby inhibiting leukemia cell proliferation and promoting cell apoptosis.

Clinical studies have shown that giritinib has significant efficacy in patients with relapsed or refractory FLT3mutantAML. In the ADMIRAL trial, the overall response rate (including complete response CR and complete response with incomplete blood cell recovery) in patients treated with giritinib CRi) reached about 34%, which was significantly higher than the CR rate of the traditional chemotherapy group. At the same time, giritinib has also shown the advantage of prolonging the median overall survival (OS), bringing significant survival benefits to patients.

Giritinib is not only effective as a monotherapy, but can also be used in combination with chemotherapy or other targeted drugs to enhance efficacy. In patients with newly treated or relapsed AML, combination therapy can further improve the remission rate, and at the same time improve the patient's conditions for stem cell transplantation by reducing the leukemia burden, providing the possibility of long-term survival. Clinicians will develop individualized treatment plans based on the patient's genetic mutation type, age and physical condition.

Overall, giritinib provides an important targeted therapy option for patients with FLT3 mutantAML. Its safety and efficacy have been verified in multiple clinical trials, but patients still need to regularly monitor hematological indicators, liver and kidney function, and electrocardiogram during use to ensure the safety of treatment and adjust the dosage in a timely manner to maximize the efficacy and reduce the risk of side effects.

Reference materials:https://www.drugs.com/